Goldman Sachs’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.1M | Sell |
197,945
-7,282
| -4% | -$728K | ﹤0.01% | 2476 |
|
|
2025
Q4 | $20M | Buy |
205,227
+55,426
| +37% | +$4.75M | ﹤0.01% | 2371 |
|
|
2025
Q3 | $10.7M | Buy |
149,801
+6,099
| +4% | +$406K | ﹤0.01% | 2894 |
|
|
2025
Q2 | $8.59M | Sell |
143,702
-25,685
| -15% | -$1.41M | ﹤0.01% | 2894 |
|
|
2025
Q1 | $8.89M | Buy |
169,387
+1,821
| +1% | +$102K | ﹤0.01% | 2803 |
|
|
2024
Q4 | $9.22M | Buy |
167,566
+10,617
| +7% | +$559K | ﹤0.01% | 2883 |
|
|
2024
Q3 | $7.89M | Buy |
156,949
+77,956
| +99% | +$3.6M | ﹤0.01% | 2936 |
|
|
2024
Q2 | $3.47M | Buy |
78,993
+45,712
| +137% | +$1.94M | ﹤0.01% | 3491 |
|
|
2024
Q1 | $1.46M | Sell |
33,281
-20,802
| -38% | -$919K | ﹤0.01% | 4082 |
|
|
2023
Q4 | $2.57M | Sell |
54,083
-1,993
| -4% | -$83.8K | ﹤0.01% | 3731 |
|
|
2023
Q3 | $2.49M | Buy |
56,076
+9,109
| +19% | +$423K | ﹤0.01% | 3594 |
|
|
2023
Q2 | $2.24M | Sell |
46,967
-1,638
| -3% | -$73.9K | ﹤0.01% | 3791 |
|
|
2023
Q1 | $1.91M | Sell |
48,605
-6,645
| -12% | -$242K | ﹤0.01% | 3897 |
|
|
2022
Q4 | $1.56M | Buy |
55,250
+9,184
| +20% | +$263K | ﹤0.01% | 4117 |
|
|
2022
Q3 | $1.39M | Buy |
46,066
+8,643
| +23% | +$301K | ﹤0.01% | 4287 |
|
|
2022
Q2 | $1.27M | Buy |
37,423
+2,918
| +8% | +$105K | ﹤0.01% | 4426 |
|
|
2022
Q1 | $1.55M | Buy |
34,505
+20,265
| +142% | +$937K | ﹤0.01% | 4451 |
|
|
2021
Q4 | $659K | Sell |
14,240
-231
| -2% | -$9.32K | ﹤0.01% | 5181 |
|
|
2021
Q3 | $486K | Buy |
14,471
+7,326
| +103% | +$249K | ﹤0.01% | 5218 |
|
|
2021
Q2 | $210K | Buy |
+7,145
| New | +$197K | ﹤0.01% | 5719 |
|
|
2019
Q2 | – | Sell |
-9,344
| Closed | -$262K | – | 5235 |
|
|
2019
Q1 | $262K | Sell |
9,344
-3,019
| -24% | -$79K | ﹤0.01% | 4685 |
|
|
2018
Q4 | $302K | Buy |
12,363
+2,433
| +25% | +$65.4K | ﹤0.01% | 4632 |
|
|
2018
Q3 | $369K | Sell |
9,930
-1,971
| -17% | -$53.2K | ﹤0.01% | 4588 |
|
|
2018
Q2 | $247K | Buy |
+11,901
| New | +$210K | ﹤0.01% | 4885 |
|
|
2017
Q2 | – | Sell |
-32,619
| Closed | -$290K | – | 6852 |
|
|
2017
Q1 | $290K | Buy |
+32,619
| New | +$302K | ﹤0.01% | 5489 |
|
|
2015
Q4 | – | Sell |
-9,263
| Closed | -$226K | – | 7242 |
|
|
2015
Q3 | $226K | Sell |
9,263
-3,322
| -26% | -$79.5K | ﹤0.01% | 5895 |
|
|
2015
Q2 | $293K | Sell |
12,585
-2,819
| -18% | -$51.5K | ﹤0.01% | 5763 |
|
|
2015
Q1 | $235K | Buy |
15,404
+1
| +0% | +$15 | ﹤0.01% | 5873 |
|
|
2014
Q4 | $199K | Sell |
15,403
-4,703
| -23% | -$40.6K | ﹤0.01% | 6159 |
|
|
2014
Q3 | $141K | Buy |
+20,106
| New | +$182K | ﹤0.01% | 6410 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Goldman Sachs's IRMD Position: Q1 2026 in Review
Goldman Sachs reduced its iRadimed (IRMD) stake by 3.5% in Q1 2026, selling an estimated $728K and leaving 197,945 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2476.
Goldman Sachs first reported a position in IRMD in Q3 2014 and has held it in 30 quarters since. The position peaked at $20M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Goldman Sachs held 197,945 shares of iRadimed worth $19.1M as of Q1 2026.
- Goldman Sachs sold 7,282 iRadimed shares in Q1 2026, an estimated $728K.
- iRadimed made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2476 holding.
- Goldman Sachs first reported a position in iRadimed in Q3 2014 and has held it in 30 quarters since.
- Goldman Sachs's iRadimed position peaked at $20M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.